A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3–4 weeks, the aim of the current study...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, H.K., Ottewell, P.D., Evans, C.A., Coleman, R.E., Holen, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723328/
https://www.ncbi.nlm.nih.gov/pubmed/26909255
http://dx.doi.org/10.1016/j.jbo.2012.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723328/
https://www.ncbi.nlm.nih.gov/pubmed/26909255
http://dx.doi.org/10.1016/j.jbo.2012.05.001

Ejemplares similares